MR imaging findings of low-grade serous carcinoma of the ovary: comparison with serous borderline tumor

2020 ◽  
Vol 38 (8) ◽  
pp. 782-789
Author(s):  
Masaya Kawaguchi ◽  
Hiroki Kato ◽  
Yuichiro Hatano ◽  
Hiroyuki Tomita ◽  
Akira Hara ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
Imaging Findings ◽  
Serous Borderline Tumor ◽  
Carcinoma Of The Ovary

Malignant Transformation of a Serous Borderline Tumor and Early Metastasis of Associated Low-Grade Serous Carcinoma Detected on Screening Mammography

2011 ◽  
Vol 29 (30) ◽  
pp. e763-e765 ◽  
Author(s):  
Donata Rohsbach ◽  
Fabian Trillsch ◽  
Marc Regier ◽  
Matthias Choschzick ◽  
Friedrich Kommoss ◽  
...  
Keyword(s):  
Malignant Transformation ◽  
Screening Mammography ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
Early Metastasis ◽  
Serous Borderline Tumor

scholarly journals Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1630
Author(s):  
Mariana Rei ◽  
Sofia Raposo ◽  
Paulo Figueiredo ◽  
Rita Sousa ◽  
Luís Sá
Keyword(s):  
Tumor Biology ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
High Grade ◽  
Peritoneal Carcinoma ◽  
Non Invasive ◽  
Serous Borderline Tumor ◽  
And Behavior ◽  
Serous Tumors

Ovarian borderline serous tumors present with peritoneal involvement in 20% of cases, either as non-invasive or invasive implants, the latter also known as extraovarian low-grade serous carcinoma. The coexistence of high-grade serous carcinoma is rare, suggesting a synchronous neoplasia with a distinct and independent tumor biology and behavior. We aim to describe a case of a synchronous ovary-peritoneum neoplasia: serous borderline tumor and primary peritoneal high-grade serous carcinoma. A discussion and literature review concerning the optimal diagnostic and therapeutic approach is provided.

scholarly journals Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1630
Author(s):  
Mariana Rei ◽  
Sofia Raposo ◽  
Paulo Figueiredo ◽  
Rita Sousa ◽  
Luís Sá
Keyword(s):  
Tumor Biology ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Borderline Tumor ◽  
High Grade ◽  
Peritoneal Carcinoma ◽  
Non Invasive ◽  
Serous Borderline Tumor ◽  
And Behavior ◽  
Serous Tumors

Ovarian borderline serous tumors present with peritoneal involvement in 20% of cases, either as non-invasive or invasive implants, also known as extraovarian low-grade serous carcinoma. The coexistence of high-grade serous carcinoma is rare, suggesting a synchronous neoplasia with a distinct and independent tumor biology and behavior. We aim to describe a case of a synchronous ovary-peritoneum neoplasia: serous borderline tumor and primary peritoneal high-grade serous carcinoma. A discussion and literature review concerning the optimal diagnostic and therapeutic approach is provided.

A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. TPS5601-TPS5601
Author(s):  
Amanda Nickles Fader ◽  
Lilian Tran Gien ◽  
Austin Miller ◽  
Al Covens ◽  
David Marc Gershenson
Keyword(s):  
Clinical Trial ◽  
Maintenance Therapy ◽  
Aromatase Inhibitor ◽  
The United States ◽  
Stage Ii ◽  
Phase Iii ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Information Time ◽  
Carcinoma Of The Ovary

TPS5601 Background: Low-grade serous carcinoma of the ovary or peritoneum (LGSOC) is a rare subtype of epithelial carcinoma. Differences in epidemiology, pathogenesis, disease presentation, and clinical outcomes have been characterized between women diagnosed with LGSOC and those with the p53-driven high-grade serous carcinoma (HGSOC). Ultimately, patients with LGSOC should be treated differently than those with HGSOC. Several studies suggest that LGSOC is relatively chemoresistant and that most tumors robustly express estrogen and progesterone receptors. Recently, retrospective reports suggest that utilization of the aromatase inhibitor, letrozole, as monotherapy or in addition to platinum/taxane-based chemotherapy in those with primary advanced-stage LGSOC results in preliminarily promising survival outcomes. Methods: This study is a two-arm, randomized, open-label, Phase III clinical trial. The primary objective is to assess whether letrozole monotherapy (2.5 mg po daily) is non-inferior to carboplatin (AUC 5-6) and paclitaxel (175 mg/m2) followed by letrozole maintenance therapy with respect to progression free survival in women with primary, Stage II-IV LGSOC who have undergone an attempt at maximal surgical cytoreduction. Secondary endpoints include incidence of adverse events, objective response rate in those with measurable disease after surgery, response duration, overall survival, and adherence to letrozole maintenance therapy. Study subjects must have undergone a bilateral salpingo-oophorectomy, and p53 IHC testing of tumors is required to rule out those with aberrant p53 expression commonly observed in HGSOC tumors. Study strata include residual disease status and country of enrollment. Four hundred and fifty patients will be enrolled in the United States, Canada and South Korea through the NRG Oncology trials network. Correlative aims include analyzing the association of ER/PR tumoral expression with aromatase inhibitor therapy response and determining ESR1 mutational status in those who develop letrozole resistance. The study includes two interim analyses; at 20% information time, a futility analysis will be conducted, and at 40% information time, both efficacy and futility will be assessed. This is one of the first randomized trials performed in women with primary, advanced LGSOC, and the study is open with 71 patients enrolled at the time of abstract submission. Clinical trial information: NCT04095364.

Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis

2013 ◽  
Vol 32 (6) ◽  
pp. 529-535 ◽  
Author(s):  
Rola H. Ali ◽  
Steve E. Kalloger ◽  
Jennifer L. Santos ◽  
Kenneth D. Swenerton ◽  
C. Blake Gilks
Keyword(s):  
Poor Prognosis ◽  
Stage Ii ◽  
Serous Carcinoma ◽  
Low Grade ◽  
Carcinoma Of The Ovary

A Micropapillary Variant of Transitional Cell Carcinoma Arising in the Ureter

2000 ◽  
Vol 124 (9) ◽  
pp. 1347-1348 ◽  
Author(s):  
Russell Vang ◽  
Jacki Abrams
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Inflammatory Cells ◽  
World Health ◽  
Serous Carcinoma ◽  
Ureteral Stricture ◽  
Borderline Tumor ◽  
Nephrogenic Adenoma ◽  
Serous Borderline Tumor

Abstract A 79-year-old woman was evaluated for a ureteral stricture related to laser ablation of a tumor 6 months earlier at another institution. A ureteroscopic examination revealed an exophytic papillary tumor that was resected and examined histologically. The tumor was characterized by delicate papillae with thin stromal cores and numerous secondary micropapillae lined by small cuboidal to low columnar cells with uniform low-to-intermediate–grade nuclei, reminiscent of a serous borderline tumor of müllerian origin. The cell linings were 1 to 4 layers thick; mitotic figures were easily identified. The underlying stroma appeared edematous and contained scattered chronic inflammatory cells. No invasion was identified. After ascertaining that the patient had no known gynecologic neoplasm, the differential diagnoses considered included papillary nephrogenic adenoma, clear cell carcinoma, and the recently described entity of micropapillary transitional cell carcinoma. Because of the striking resemblance to serous carcinoma and the presence of significant mitotic activity, this case was felt to represent a case of micropapillary transitional cell carcinoma (World Health Organization grade 1 to 2) occurring in the ureter. To our knowledge, this tumor had some unique features (no areas of grade 3 nuclei or invasion) that have not been reported in tumors occurring in the urinary bladder. The transitional cell nature of the tumor cells was supported by the immunohistochemical staining pattern. The anatomic distribution of micropapillary transitional cell carcinoma is now expanded to include the ureter, and this tumor should be considered in the differential diagnosis for papillary lesions occurring in the ureter.

Sign in / Sign up

Export Citation Format

Share Document